UK markets closed
  • FTSE 100

    -54.52 (-0.94%)
  • FTSE 250

    -241.71 (-1.35%)
  • AIM

    -3.65 (-0.37%)

    +0.0024 (+0.22%)

    +0.0042 (+0.33%)

    +324.52 (+3.22%)
  • CMC Crypto 200

    +8.78 (+3.36%)
  • S&P 500

    -5.27 (-0.15%)
  • DOW

    -143.96 (-0.52%)

    +0.97 (+2.52%)

    +3.90 (+0.20%)
  • NIKKEI 225

    -8.54 (-0.04%)

    -131.59 (-0.53%)
  • DAX

    -103.79 (-0.85%)
  • CAC 40

    -75.81 (-1.57%)


·8-min read

DGAP-News: Evotec SE / Key word(s): Capital Increase
13.10.2020 / 00:40
The issuer is solely responsible for the content of this announcement.


Hamburg, Germany, 13 October 2020:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that it resolved a capital increase from its authorised capital without pre-emptive rights against cash. Evotec will issue a total of 11,478,315 new shares to Mubadala Investment Company and Novo Holdings A/S, increasing Evotec's cash reserves by € 250 million in total.

In this private placement capital increase, Mubadala Investment Company, a sovereign investor with an entrepreneurial mind-set and a long-standing history of strategic investments in the healthcare sector, will invest € 200 million to subscribe for approx. 5.6% of outstanding Evotec shares. Evotec's existing shareholder Novo Holdings A/S also will invest € 50 million to support Evotec's accelerated growth ambition and to reinforce its ownership in the company of approx. 11.0% of outstanding shares. The shares will be issued at a price of € 21.7802 per share, which represents a 2.5% discount to the five-day volume weighted average price ("VWAP") of € 22.3387 prior to the Xetra closing auction on 12th October 2020. After the registration of the capital increase in the commercial register, Evotec's share capital will increase to € 163,375,808, or 163,375,808 ordinary bearer shares.

Evotec has developed a unique strategy to become the global leading platform company for the modality-agnostic development of innovative first-in-class and best-in-class therapeutic approaches resulting in a large co-owned pipeline. Evotec has continuously expanded its operations internationally with more than 3,400 employees at 14 global sites in Germany, USA, France, Italy, UK, and Austria. By leveraging its proprietary platforms within a comprehensive network of high-value partnerships, Evotec aims to improve global access to more precise and effective medicines. Future investments will accelerate Evotec's underlying business strategy and enable the company's next strategic growth phase.

The company is evaluating - inter alia - investment opportunities such as:

Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: "We welcome Mubadala to our group of strategic investors. There is no reason for us to slow down our mission in spite of the ongoing pandemic. We can and want to grow even faster and see a lot of positive momentum in our business strategy. We are delighted that Mubadala has chosen to invest in Evotec with a long-term view. Also, we are pleased to see that Novo Holdings A/S continues to support our strategy. This investment allows us to further accelerate our strategy to create the world-leading "R&D Autobahn to Cures" from discovery to commercial manufacturing."

Enno Spillner, Chief Financial Officer of Evotec, added: "With this commitment by existing and new investors, our liquidity reserves will total more than € 500 m. Thus this placement will generate a net cash position of more than € 150 m (excluding IFRS 16) with Evotec's net-debt leverage turning negative (excluding IFRS 16). Our equity ratio will strengthen to above 50%. While maintaining our business outlook for 2020, the very positive impact of this transaction on our balance sheet structure will increase our flexibility and makes us even better prepared for our accelerated global expansion steps."

Camilla Macapili Languille, Head of Pharma & Medtech at Mubadala Investment Company, commented: "We are excited to partner with Evotec, who we see as one of the global pioneers for drug discovery innovation. We have been impressed by the quality and depth of Evotec's management team, the company's distinctive business model, their proprietary technological platforms and the unique role they play in the rapidly growing universe of pharmaceutical & biotech R&D - an area whose importance is acutely highlighted in the current environment. We will work with the company and its shareholders to support Evotec's strategic growth both through this investment and our extensive institutional network."

Anders Bendsen Spohr, Senior Partner Principal Investments at Novo Holdings, commented: "As a longtime investor in Evotec, we are very proud of the company's accomplishments to date. We are strong believers in Evotec's business model and modality-agnostic approach to drug discovery, and look forward to continue to support the company in its next strategic growth phase through this additional capital commitment and our broad life science network."

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 3,400 employees provide the highest quality stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare diseases and women's health. On this basis, Evotec has built a broad and deep pipeline of approx. 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to and follow us on Twitter @Evotec.

Mubadala Investment Company is a sovereign investor managing a global portfolio, aimed at generating sustainable financial returns for the Government of Abu Dhabi.

Mubadala's $232 billion (AED 853 billion) portfolio spans six continents with interests in multiple sectors and asset classes. We leverage our deep sectoral expertise and long-standing partnerships to actively source deals. In the UAE, we are driving sustainable growth by optimizing scale and efficiency, supporting the continued diversification and global integration of the local economy while growing our shareholder value.

Headquartered in Abu Dhabi, Mubadala has offices in London, Rio de Janeiro, Moscow, New York, San Francisco and Beijing. Further information:

Press Contacts:
Rashed Alharmoodi
Head of External Corporate Relations
Mubadala Investment Company
M: +971 55 7007431

Novo Holdings A/S is a private limited liability company wholly owned by the Novo
Nordisk Foundation. It is the holding company of the Novo Group, comprising Novo Nordisk A/S and
Novozymes A/S, and is responsible for managing the Novo Nordisk Foundation's assets.

Novo Holdings is recognized as a leading international life science investor, with a focus on creating
long-term value. As a life science investor, Novo Holdings provides seed and venture capital to
development-stage companies and takes significant ownership positions in growth and

well-established companies. Novo Holdings also manages a broad portfolio of diversified
financial assets. Further information:

Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

Media Contact Evotec SE:
Gabriele Hansen, SVP Head of Global Corporate Communications & Marketing, Phone: +49.(0)40.56081-255,

13.10.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at




Evotec SE

Manfred Eigen Campus / Essener Bogen 7

22419 Hamburg



+49 (0)40 560 81-0


+49 (0)40 560 81-222










Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange

EQS News ID:



End of News

DGAP News Service

show this
show this